Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has r...
StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, recently announced the s...
HitGen has announced that the company has entered into a research collaboration with Almirall to identify novel small mo...
BioInvent International AB, focused on the discovery and development of novel and first-in-class immuno-regulatory antib...
Roche announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with mod...
Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical research and development company, and twoXAR, Inc., a US based a...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics Licen...
The U.S. Food and Drug Administration has approved Spravato (esketamine) nasal spray, in conjunction with an oral antide...
Glenmark Pharmaceuticals has announced the presentation of a new post hoc analysis of data from a Phase 2a, proof-of-con...
Merck and Pfizer Inc. has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review...
Teva Pharmaceutical Industries has announced the launch of a generic version of Sabril®1 (vigabatrin) tablets, ...
Perrigo Company plc has announced it has received final approval from the U.S. Food and Drug Administration for its AB r...
BioLineRx Ltd., an Israeli clinical-stage biopharmaceutical company focused on oncology, announced that the U.S. Food an...
Reaction Biology Corporation ("RBC") and ChinaEquity Group ("CEG") have announced the conclusion of a stock exchange tra...
I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the developm...
Eli Lilly and Companyhas announced that USFDA has granted approval for a new indication for ALIMTA® (pemetrexed...
Neurocrine Biosciences and Voyager Therapeutics has announced the formation of a strategic collaboration focused on the ...
Pfizer and Eli Lilly have announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg i...
